Amber Tong – Page 91 – Endpoints News

about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW

Amber Tong on LinkedIn

author articles

NeuroRx secures $95M to fund PhIII for NMDA depression drug; Trump revives science advisory council

6 years ago

Jean-Paul Clozel downplays recruitment delays holding up PhIII for Fabry disease

6 years ago

Soriot, Schleifer, Perreault named top global CEOs — but gone are pharma's golden years

6 years ago

CD47 player Trillium chops discovery efforts and 40% of staff; Brii Bio inks deal to bring antibiotics to China

6 years ago

Frazier Healthcare Partners' dermatology upstart attracts a marquee syndicate, $94M+ for 'in-between' topical drug

6 years ago

Failed PhIII fevipiprant trials pour more cold water on Novartis' blockbuster R&D engine — and briefly spread the ...

6 years ago

Sofinnova-backed Abivax touts longer term mid-stage data in ulcerative colitis

6 years ago

Alexion clinches aHUS approval for Ultomiris as the clock ticks on Soliris conversion

6 years ago

Armed with Langer tech and $50M, Verseau hails new checkpoint drugs unleashing macrophages against cancer

6 years ago

Merck KGaA wants to get in early on Chinese innovation — so it's setting up a seed fund there

6 years ago

As Osiris moves on from fraudulent past, one exec settles up with SEC

6 years ago

PhI fizzle forces Syros to spike its lead drug, triggering another rout on shares

6 years ago

Despite worries triggered by imbalance of deaths, Shionogi's antibiotic clears FDA panel vote

6 years ago

San Diego upstart debuts discovery engine that puts a twist to protein degradation

6 years ago

Floating in stormy seas, RTW seeks $350M for new London-listed venture fund

6 years ago

Woodford fired from flagship fund — which won't reopen after all

6 years ago

BridgeBio drops bid to reclaim Eidos after directors spurn 3 offers

6 years ago

Eyeing $86M, Galera leads a pack of three modest biotech IPOs pushing past high profile stumbles

6 years ago

Microcap Aridis recruits Takeda vet Paul Mendelman to steer late-stage antibody programs in infectious diseases

6 years ago

Roche vice-chair: Let's repair the damage that short-term profit drive has done to the planet

6 years ago

Flow of US biotech VC dollars on track to match record 2018 levels — China? Not so much

6 years ago

Parexel embraces real world evidence, enlisting Datavant to drill it into CRO workflow

6 years ago

Shionogi celebrates antibiotic win in pneumonia just ahead of its date with FDA regulators

6 years ago

BioMarin puts Lon Cardon in charge of portfolio strategy while gene therapy filings get underway

6 years ago

First page Previous page 88 89 909192 93 94 Next page Last page